Gilead said Tuesday morning it will acquire German startup Tubulis in a deal worth $3.15 billion upfront, with as much as another $1.85 billion available to Tubulis shareholders if the business performs as expected. The agreement makes Tubulis Gilead’s third acquisition of 2026 and adds another major bet on antibody-drug conjugates, or ADCs, after a two-year partnership between the companies.
Gilead CEO and chair Dan O’Day said that tie-up gave the company “strong conviction in their programs and research capabilities,” a judgment that now comes with one of the larger checks Gilead has written in recent years. Tubulis had raised a $401 million Series C last year and had been weighing a possible IPO, while also bringing in Roche oncology executive Charles Fuchs as chief medical officer.
The deal centers on a pipeline built around ADCs, a class of targeted cancer medicines that links an antibody to a toxic payload. Tubulis’ lead program, TUB-040, is a Phase 1b/2 NaPi2b-directed ADC in development for certain forms of ovarian cancer and is also being tested in non-small cell lung cancer. The company is also advancing TUB-030, a 5t4-targeted ADC being tested in various solid tumors, along with additional preclinical candidates including a degrader antibody conjugate.
Read Also: UBS Reiterates Unh Stock Buy, Sets $410 Price Target
Dominik Schumacher, Tubulis’ chief executive and founder, has said the company wants to “push the boundaries of ADCs” and “tailor-make” the medicines it develops, language that captures why Gilead is buying rather than building from scratch. Tubulis said its Munich site will become the hub of Gilead’s ADC innovation, giving the drugmaker a European center for work in one of oncology’s hottest areas.
The acquisition follows Gilead’s mixed history in the field. In 2020, it spent $21 billion on Immunomedics, a purchase that delivered Trodelvy and other candidates, but Trodelvy has since suffered a series of clinical setbacks in several cancer settings. Gilead pulled Trodelvy’s accelerated bladder cancer label last year, a reminder that even a large acquisition can leave a company without the results it expected.
Read Also: Mortgage Officer Shant Banosian Takes Top Spot in 2026 Rankings
That backdrop makes the Tubulis deal more than a simple expansion move. Gilead is not just adding a pipeline; it is trying to prove that its next round of oncology buying can produce steadier returns than the last. The transaction is slated to close this quarter, and the real test will come after the paperwork is done: whether Tubulis’ programs can deliver the kind of data that made Gilead comfortable paying up now.